Successful short-term peg-interferon monotherapy for chronic hepatitis

April 8, 2010

The standard duration of interferon therapy for chronic hepatitis C could be shortened according to the virological and clinical status of each patient. A research group in Japan proposed a new concept, "immediate virological response (IVR)", and showed that short-term peg-interferon monotherapy was highly effective for patients with low viral load and IVR. Hepatitis C virus was eliminated in 92.1 percent of patients.

The efficacy of interferon (IFN) therapy depends on the hepatitis C virus (HCV) genotype, pretreatment viral load and early viral kinetics. Thus, IFN therapy must be individualized and optimized according to the virological and clinical status of each patient.

A research article to be published on March 28, 2010 in the addresses this question. Dr. Masumoto and his colleagues at Iizuka Hospital proposed the new concept of early viral kinetics in peg-interferon (PEG-IFN) therapy. They defined the "immediate virological response (IVR)" as the loss of serum HCV RNA 7 days after the first administration of PEG-IFN, and scheduled a 12-week treatment course of PEG-IFN for 38 patients who had low pretreatment HCV RNA load and exhibited IVR. As a result, 35 patients (92.1%) achieved sustained virological response (SVR); the elimination of HCV.

Establishing the minimum and yet sufficient IFN therapy period is essential in terms of financial efficiency and for reducing the risk of adverse events. The results of this study provide an important suggestion which will allow future investigations to optimize the treatment regimen of IFN therapy for chronic , especially for the patients who exhibit fast virological response to IFN. IVR, the new concept proposed in this study, should be a simple and useful indicator of early viral kinetics to predict the high probability of SVR.

More information: Yada M, Masumoto A, Yamashita N, Motomura K, Koyanagi T, Sakamoto S. Immediate virological response predicts the success of short-term peg-interferon monotherapy for chronic hepatitis C. World J Gastroenterol 2010; 16(12): 1506-1511 www.wjgnet.com/1007-9327/full/v16/i12/1506.htm

Related Stories

Recommended for you

Zika in fetal brain tissue responds to a popular antibiotic

November 30, 2016

Working in the lab, UC San Francisco researchers have identified fetal brain tissue cells that are targeted by the Zika virus and determined that azithromycin, a common antibiotic regarded as safe for use during pregnancy, ...

Zika and glaucoma linked for first time in new study

November 30, 2016

A team of researchers in Brazil and at the Yale School of Public Health has published the first report demonstrating that the Zika virus can cause glaucoma in infants who were exposed to the virus during gestation.

Flu forecasts successful on neighborhood level

November 30, 2016

Scientists at Columbia University's Mailman School of Public Health developed a computer model to predict the onset, duration, and magnitude of influenza outbreaks for New York City boroughs and neighborhoods. They found ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.